Leerink Partnrs Issues Positive Estimate for BBIO Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for shares of BridgeBio Pharma in a note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($0.72) per share for the quarter, up from their prior estimate of ($0.73). The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($3.24) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at $0.61 EPS, FY2028 earnings at $3.28 EPS and FY2029 earnings at $4.88 EPS.

BBIO has been the subject of several other research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $95.00 price target on shares of BridgeBio Pharma in a research note on Friday, February 21st. Citigroup boosted their target price on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Evercore ISI boosted their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a report on Monday, December 23rd. HC Wainwright reiterated a “buy” rating and issued a $49.00 price objective on shares of BridgeBio Pharma in a report on Thursday, February 13th. Finally, Scotiabank upped their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a report on Friday, February 21st. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $51.67.

BridgeBio Pharma Stock Performance

NASDAQ BBIO opened at $34.90 on Friday. BridgeBio Pharma has a fifty-two week low of $21.62 and a fifty-two week high of $39.47. The stock has a 50-day simple moving average of $32.68 and a two-hundred day simple moving average of $28.29. The firm has a market capitalization of $6.64 billion, a P/E ratio of -12.25 and a beta of 1.07.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million.

Insider Transactions at BridgeBio Pharma

In related news, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $34.90, for a total value of $106,989,998.40. Following the transaction, the insider now owns 22,055,375 shares of the company’s stock, valued at $769,732,587.50. This represents a 12.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Neil Kumar sold 326,932 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the completion of the transaction, the chief executive officer now owns 5,371,515 shares of the company’s stock, valued at $194,932,279.35. This represents a 5.74 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,579,739 shares of company stock valued at $125,411,901. 24.66% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BridgeBio Pharma

Several hedge funds have recently made changes to their positions in BBIO. Jefferies Financial Group Inc. purchased a new position in BridgeBio Pharma during the fourth quarter worth about $5,076,000. Mackenzie Financial Corp increased its holdings in BridgeBio Pharma by 6.6% in the fourth quarter. Mackenzie Financial Corp now owns 9,505 shares of the company’s stock valued at $261,000 after buying an additional 592 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of BridgeBio Pharma during the 4th quarter worth approximately $109,000. Frazier Life Sciences Management L.P. increased its stake in shares of BridgeBio Pharma by 1.1% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock worth $104,285,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Woodline Partners LP increased its stake in shares of BridgeBio Pharma by 132.9% during the 4th quarter. Woodline Partners LP now owns 2,211,521 shares of the company’s stock worth $60,684,000 after purchasing an additional 1,261,772 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.